News & Events
Results from a long-term observational study on MS
Long-term follow-up studies could help determine predictive factors for long-term clinical outcomes
Improving clinical trial designs in MS
Study suggests that longer observation time is necessary for more reliable results
Recommended treatment after stopping natalizumab
Switching from natalizumab to an alternative drug may prevent disease reactivation
Your chance to ask a young researcher about his work
Arman Eshaghi will answer your questions
New drug tested for relapsing-remitting MS
Results show daclizumab to be effective in reducing relapse rate and new lesions in relapsing-remitting MS
ABEM works with Brazilian mental health initiative
Brazilian MS Association ABEM is taking part in a campaign to highlight the importance of mental health…
Multiple Sclerosis Ireland launches report on the hidden costs of MS
On 21st October, MS Ireland launched a report on the costs of multiple sclerosis to Irish society
Global Patient Solidarity Day & UN Day for people with Disabilities
There are two World Days coming up which will be of interest to the global MS community.
Cast your vote
Which of these MS research areas would you like to hear more about?
Interview with Mauricio Farez
We spoke to an Argentinian researcher studying the correlation between melatonin and MS
New target for understanding secondary progressive MS
Chemical in the brain involved in signaling may play a role in progressive MS
Fingolimod safety and efficacy confirmed
The results of a seven-year follow-up study confirm the safety and efficacy of fingolimod